LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients
Authors: X Wang
Y-X Tang
Q-F Xu
Journal: European review for medical and pharmacological sciences (2018)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: Ovarian cancer; lncRNA EBIC; prognosis; metastasis; proliferation
Affiliations: Department of Pharmacy, West China Second Hospital, Sichuan University, Chengdu, China. .

Abstract:  Objective: Ovarian cancer has the highest mortality rate cancer worldwide in women, and it is the second most common gynecologic malignancy in females, but the treatment remained unsatisfactory. Researches showed that lncRNA EBIC had played key roles in different cancer, but its role in ovarian cancer remains largely unclear. Patients and methods: qRT-PCR was applied to detect the expression of lncRNA EBIC in ovarian cancer and adjacent tissue, and analysis was applied to explore the relationship between expression and clinical characteristic. Overall, the survival curves for the two groups were defined by the high and low expression level of EBIC in ovarian cancer patients. After that, CCK8 and transwell were used to detect the proliferation and metastasis ability of ovarian cancer, after suppression of lncRNA EBIC. The relative protein expression level in ovarian cancer cells after transfection with siRNA-NC or siRNA-EIBC was detected by Western blot. Results: qRT-PCR showed that lncRNA EIBC was highly expressed in ovarian cancer tissue, compared with adjacent tissue. Moreover, we found that expression of lncRNA EIBC was closely related to prognosis, tumor size and lymph node metastasis. We also found that the cell proliferation, invasion, migration and cisplatin resistance in ovarian cancer cells after transfection with siRNA-EBIC were significantly inhibited. Mechanistically, the relative protein expression level of β-catenin, vimentin and c-myc were significantly decreased and the relative expression of E-cadherin was significantly increased in ovarian cancer cells after transfection with siRNA-EBIC. Conclusions: We found that overexpression of lncRNA EBIC could promote the proliferation, invasion and migration and improved cells cisplatin resistance by Wnt/β-catenin signaling pathway in ovarian cancer. LncRNA EBIC may be a potential target for the treatment of ovarian cancer patients. 

Retracted: No

PubPeer comments:
 From the Methods:  The data were collected from 126 patients with ovarian cancer admitted in the hospital from June 2015 to December 2016. The paper was published in July 2018, three years after recruitment of the first patients. Yet, Figure 1D shows that the patients were followed for more than 10 years ( 120 months). Could the authors please clarify how this is possible? ![file] , 
 Looking at the data presented in Figures 1A-C, can the authors clarify how in Figure 1A the average EBIC expression in tumors was found to be ~62, while in panels B and C the average appears to be much lower? , 
  The data were collected from 126 patients with ovarian cancer admitted in the hospital from June 2015 to December 2016. [...] This research was approved by the Medical Ethics Committee. I am surprised that the authors didn t specify **which** hospital, and **which** Ethics Committee, as they are spread across two institutions (West China Second Hospital, Sichuan University, and The Third Affiliated Hospital of Chongqing Medical University). ,